Long-Term Follow-Up of Denosumab Discontinuers with Multiple Vertebral Fractures in the Real-World: A Case Series
Horm Metab Res DOI: 10.1055/a-1368-4218Denosumab discontinuation is associated with rapid reversal of bone turnover suppression and with a considerable increase in fracture risk, including a risk for multiple vertebral fractures (MVF). Long-term follow-up of patients who sustained MVF after denosumab discontinuation has not been reported. This case-series was aimed to provide a long-term follow-up on the management and outcome of denosumab discontinuers who initially presented with multiple vertebral fractures. Denosumab discontinuers were identified from a computerized database of a large healthcare provider. Baseline and follow-up clinical, laboratory, and imaging data were obtained from the computerized database and electronic medical records. The post-denosumab discontinuers MVF patients consisted of 12 women aged 71±12. Osteoporotic fractures were prevalent before denosumab discontinuation in 6 of the patients. The majority received bisphosphonates before denosumab. MVF occurred 134±76 days after denosumab discontinuation. The patients were followed for a median of 36.5 (IQR 28.2, 42.5) months after MVF. Two patients passed-away. Two patients suffered recurrent vertebral fractures. Following MVF, patients were treated inconsistently with denosumab, teriparatide, oral, ...
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Tripto-Shkolnik, Liana Liel, Yair Yekutiel, Naama Goldshtein, Inbal Tags: Endocrine Care Source Type: research
More News: Computers | Databases & Libraries | Electronic Medical Records (EMR) | Endocrinology | Forteo | Hormones | Laboratory Medicine | Orthopaedics | Vertebroplasty | Women | Xgeva